ROCKVILLE, Md.–(BUSINESS WIRE)–SYNAPS Dx (SDx), a privately held company focused on the research, development and commercialization of a diagnostic test for Alzheimer’s disease (AD), is pleased to announce that with the acceptance of an oral presentation of “Autopsy-Confirmed Minimally Invasive Biomarker Identifies Alzheimer’s Disease Even in the Presence of Co-Morbid Pathologies” and a poster presentation of “Physicians’ Assessment of the Clinical Utility of a Novel Test to Diagnose Alzheimer’s Disease (AD),” the Company will participate at BRAINWeek 2023, September 6-8, 2023, Las Vegas.
“Upon autopsy, over 50% of people with AD have additional co-morbid pathologies of dementia, such as multi-infarct dementia, Parkinson’s disease or Frontal Lobe Dementia,” says Frank Amato, CEO and president, SDx. “At BRAINWeek, we will present specific data evaluating the ability of the Morphometric Imaging (MI) assay in DISCERN™ to accurately identify AD in people diagnosed with dementia, even in the presence of other co-morbid pathologies at autopsy. Additionally, our poster entitled “Physicians’ Assessment of the Clinical Utility of a Novel Test to Diagnose AD” will demonstrate the important autopsy-validated clinical study of the DISCERN test and its unparalleled contribution to accurately inform physician decision-making. These results show significantly higher clinician confidence in an AD diagnosis, especially in those recently diagnosed with dementia.”
The clinical utility study relied on a survey to estimate treatment decisions from a sample of 402 primary care physicians (PCPs) including 250 PCPs, 102 neurologists and 50 geriatricians. Results demonstrate that most physicians would routinely use the results of DISCERN and the test was an important attribute in physician decision-making. Compared to no DISCERN test, a positive result was associated with significantly higher clinician confidence in an AD diagnosis, even earlier in the disease.
“Our test results confirm the value of DISCERN and its positioning as a promising breakthrough for early AD diagnosis,” says Amato. “There are currently no autopsy-validated tests that are highly sensitive and highly specific for AD in early dementia or mixed dementia. While previously published data further validated with autopsies demonstrate both high specificity and high sensitivity, this is the first data assessing the ability of the MI assay to accurately distinguish AD in people with comorbid dementias.”
BRAINWeek attracts internists, neurologists, nurse practitioners, health system physician assistants, otolaryngologists, psychologists, primary care physicians, and psychiatrists treating CNS disorders to share breaking research as the population ages and the burden of caring for older adults increases.
For more information, visit SYNAPS Dx at booth #119 at BRAINWeek 2023.
About SYNAPS Dx
SYNAPS Dx is a privately held company focused on the research, development and commercialization of a diagnostic test for Alzheimer’s disease (AD). The Company offers DISCERN™, the first highly accurate, minimally invasive test supporting a clinician’s definitive diagnosis of AD versus other forms of dementia, even in people recently diagnosed with dementia. SYNAPS Dx’s laboratory is certified under the Clinical Laboratory Improvement Amendments (CLIA) as qualified to perform high complexity clinical laboratory testing. Physicians and patients seeking more information can visit https://discerntest.com/. For more information on the Company, visit https://www.synapsdx.com/. Contact: [email protected].
Contacts
Media:
Caroline Chambers
CPR Communications
[email protected]
201.641.1911 x 21